Cartesian Therapeutics (RNAC) Assets Average (2016 - 2026)

Cartesian Therapeutics (RNAC) has 11 years of Assets Average data on file, last reported at $292.4 million in Q1 2026.

• On a quarterly basis, Assets Average fell 30.72% year-over-year to $292.4 million in Q1 2026; TTM through Mar 2026 was $292.4 million, a 30.72% decrease from a year earlier, with the FY2025 full-year figure at $365.7 million, down 1.17% from the prior year.
• Assets Average for Q1 2026 stood at $292.4 million, down from $334.5 million in the prior quarter.
• Over the last five years, Assets Average for RNAC reached as high as $445.2 million in Q4 2024 and fell as low as $122.8 million in Q3 2023.
• Historically, Assets Average has averaged $272.9 million across 5 years, with a median of $292.4 million in 2026.
• Across the five-year window, Assets Average sank 32.97% in 2023 and surged 227.06% in 2024, its largest moves.
• Year by year, Assets Average stood at $172.1 million in 2022, then gained by 19.45% to $205.5 million in 2023, then jumped by 116.58% to $445.2 million in 2024, then declined by 24.85% to $334.5 million in 2025, then decreased by 12.6% to $292.4 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $292.4 million in Q1 2026, $334.5 million in Q4 2025, and $380.8 million in Q3 2025.